Share of global biopharmaceutical pipeline vs Clinical trial country use share in China
Share of global biopharmaceutical pipeline and Clinical trial country use share in China, compared over time.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in %, so they share one axis; the legend names each line.
Share of global biopharmaceutical pipeline and Clinical trial country use share
Unit: % · 5 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Share of global biopharmaceutical pipeline | 2025 | Actual | 30% |
| Share of global biopharmaceutical pipeline | 2015 | Actual | 2% |
| Clinical trial country use share | 2023 | Actual | 15% |
| Clinical trial country use share | 2021–2023 | Actual | 13% |
| Clinical trial country use share | 2019 | Actual | 10% |
Source: State Council, IQVIA · CC BY 4.0 · Share of global biopharmaceutical pipeline · Clinical trial country use share
Provenance
Where these numbers come from
Share of global biopharmaceutical pipeline
Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region.
2 observations in China · source organisations: State Council
Clinical trial country use share
Percentage of total clinical trial country uses accounted for by a given region.
3 observations in China · source organisations: IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring